Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3923]

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Prof Benjamin Besse and Dr Alex Spira

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer ( Prof Benjamin Besse and Dr Alex Spira )

Ensuring quality care for breast cancer patients globally

Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium

Ensuring quality care for breast cancer patients globally ( Dr Didier Verhoeven - University of Antwerp, Antwerp, Belgium )

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

Teclistamab for patients with heavily pretreated relapsed or refractory...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

$Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma ( Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA )$

E2108: Systemic therapy plus early local therapy versus systemic therapy alone...

Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA

E2108: Systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer ( Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA )

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy...

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA )

EAU guidelines for treating patients with advanced prostate cancer

Dr Eleni Efstathiou, Prof Álvaro Pinto, Prof Nicolas Mottet and Prof Heather...

EAU guidelines for treating patients with advanced prostate cancer ( Dr Eleni Efstathiou, Prof Álvaro Pinto, Prof Nicolas Mottet and Prof Heather Payne )

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and...

Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San...

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) ( Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, USA )

Cumulative incidence of financial hardship in metastatic colorectal cancer...

Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD ( Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA )

Denosumab in multiple myeloma patients with renal insufficiency

Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA

Denosumab in multiple myeloma patients with renal insufficiency ( Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA )

More from ecancer